Author:
Liu Wei-Ren,Tian Meng-Xin,Tang Zheng,Fang Yuan,Zhou Yu-Fu,Song Shu-Shu,Jiang Xi-Fei,Wang Han,Tao Chen-Yang,Zhou Pei-Yun,Qu Wei-Feng,Ding Zhen-Bin,Peng Yuan-Fei,Zhou Jian,Fan Jia,Shi Ying-Hong
Abstract
Abstract
Background
Immunoscore have shown a promising prognostic value in many cancers. We aimed to establish and validate an immune classifier to predict survival after curative resection of hepatocellular carcinoma (HCC) patients who have undergone curative resection.
Methods
The immunohistochemistry (IHC) classifier assay was performed on 664 patients with Barcelona Clinic Liver Cancer (BCLC) stage 0 or A HCC. A nine-feature-based HCC-IHC classifier was then constructed by the least absolute shrinkage and selection operator method. The associations between the HCC-IHC classifier and patient outcomes were assessed. Herein, a nomogram was generated from the Cox regression coefficients and evaluated by decision curve analysis.
Results
We constructed an HCC-IHC classifier based on nine features; significant differences were found between the low-HCC-IHC classifier patients and high-HCC-IHC classifier patients in the training cohort in the 5-year relapse-free survival rates (46.7% vs. 26.7%, respectively; P < 0.001). The HCC-IHC classifier-based nomogram presented better accuracy than traditional staging systems.
Conclusions
In conclusion, the HCC-IHC classifier could effectively predict recurrence in early-stage HCC patients and supplemented the prognostic value of the BCLC staging system. The HCC-IHC classifier may facilitate patient decision-making and individualise the management of postoperative patients with early-stage HCC.
Funder
National Natural Science Foundation of China
Publisher
Springer Science and Business Media LLC
Reference50 articles.
1. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J. Hepatol. 69, 182–236 (2018).
2. Yau, T., Tang, V. Y., Yao, T. J., Fan, S. T., Lo, C. M. & Poon, R. T. Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology 146, 1691.e3–1700.e3 (2014).
3. Forner, A., Reig, M. & Bruix, J. Hepatocellular carcinoma. Lancet 391, 1301–1314 (2018).
4. Chaisaingmongkol, J., Budhu, A., Dang, H., Rabibhadana, S., Pupacdi, B., Kwon, S. M. et al. Common molecular subtypes among Asian hepatocellular carcinoma and cholangiocarcinoma. Cancer Cell 32, 57.e3–70.e3 (2017).
5. Ogino, S., Cantor, M., Kawasaki, T., Brahmandam, M., Kirkner, G. J., Weisenberger, D. J. et al. CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies. Gut 55, 1000–1006 (2006).
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献